


## Z-VEID-FMK

<b>Cat. No.:</b>	HY-P1007
<b>CAS No.:</b>	210344-96-0
<b>Molecular Formula:</b>	C <sub>31</sub> H <sub>45</sub> FN <sub>4</sub> O <sub>10</sub>
<b>Molecular Weight:</b>	652.71
<b>Target:</b>	Caspase; Apoptosis
<b>Pathway:</b>	Apoptosis
<b>Storage:</b>	Stored under nitrogen, away from moisture
	Powder    -80°C    2 years
	-20°C    1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)



## BIOLOGICAL ACTIVITY

<b>Description</b>	Z-VEID-FMK (Z-VE(OMe)ID(OMe)-FMK) is a selective and irreversible caspase-6 peptide inhibitor. Z-VEID-FMK alleviates the S-(+)-ketamine-induced augmentation of caspase-6 activity, DNA fragmentation, and cell apoptosis <sup>[1][2]</sup> .
<b>In Vitro</b>	Z-VEID-FMK (Z-VE(OMe)ID(OMe)-FMK; pretreated 50 μM; for 1 h) decreases S-(+)-ketamine (200 μM; for another 16 h)-induced caspase-6 activity by 53% and apoptotic by 58%, alleviated S-(+)-ketamine-caused DNA fragmentation by 44% in HepG2 cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

- [1]. S-T Lee, et al. Apoptotic insults to human HepG2 cells induced by S-(+)-ketamine occurs through activation of a Bax-mitochondria-caspase protease pathway. *Br J Anaesth.* 2009 Jan;102(1):80-9.
- [2]. Philippe P Monnier, et al. Involvement of caspase-6 and caspase-8 in neuronal apoptosis and the regenerative failure of injured retinal ganglion cells. *J Neurosci.* 2011 Jul 20;31(29):10494-505.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA